A composition having an insulin resistance reversing component and a method of making the same

Abstract

The present application relates to the technical field of reversing insulin resistance, and particularly relates to a composition with components for reversing insulin resistance and a preparation method thereof, the composition comprising quercetin, procyanidin, malic acid, magnesium carbonate, zinc lactate and grains, and through synergistic effects of the components, the composition can reduce fasting blood glucose, fasting insulin and insulin resistance index, and improve insulin sensitivity index, and overcomes the problems in the prior art that the components of the traditional Chinese medicine composition are complex, the effective components for reversing insulin resistance and the synergistic mechanism are not clear, and the content of the effective components in the same medicine is not consistent due to the influence of the growth environment, resulting in unpredictable treatment effect.

Description

Technical Field

[0001] This invention relates to the field of insulin resistance reversal technology, and more particularly to a composition having an insulin resistance reversal component. Background Technology

[0002] Insulin is a hormone secreted by the pancreas. Its main function is to help cells absorb glucose to produce energy. Insulin resistance is a pathological condition in which the body's cells respond less responsively to insulin, making it difficult for glucose to enter cells and causing elevated blood sugar levels. Long-term hyperglycemia can lead to various diseases such as diabetes, hypertension, and hyperlipidemia.

[0003] Chinese Patent Application Publication No. CN105616955A discloses a traditional Chinese medicine for treating diabetic nephropathy. The composition contains the following ingredients: wild chrysanthemum, centella asiatica, licorice root, salvia miltiorrhiza, astragalus root, mulberry twig, mulberry fruit, notoginseng, yam, wild ganoderma lucidum, coptis chinensis, schisandra chinensis, gypsum, rehmannia root, polygonatum odoratum, poria cocos, and lycium chinense root bark. The above-mentioned herbs are decocted in water, the dregs are filtered out, and the decoction is taken orally. This composition can be used to treat diabetic nephropathy.

[0004] The existing technology also has the following problems: the composition of traditional Chinese medicine compositions is complex, the effective components that can reverse insulin resistance and the synergistic mechanism are unclear, and the content of effective components in the same drug is inconsistent due to the influence of the growth environment, resulting in unpredictable treatment effects. Summary of the Invention

[0005] Therefore, the present invention provides a composition containing an insulin resistance reversing component to overcome the problems of complex composition of traditional Chinese medicine compositions in the prior art, unclear effective components and synergistic mechanisms for reversing insulin resistance, and inconsistent content of effective components in the same drug due to the influence of the growth environment, resulting in unpredictable therapeutic effects.

[0006] To achieve the above objectives, in a first aspect, the present invention provides a composition having an insulin resistance reversal component, said composition comprising quercetin, proanthocyanidins, malic acid, magnesium carbonate, zinc lactate, and cereals.

[0007] Further, the composition comprises, by weight, 27-36 parts quercetin, 23-31 parts proanthocyanidins, 20-24 parts malic acid, 1.5-2 parts magnesium carbonate, 0.2-0.6 parts zinc lactate, and 100-150 parts cereals.

[0008] Further, the composition comprises, by weight, 34 parts quercetin, 25 parts proanthocyanidins, 21.5 parts malic acid, 1.7 parts magnesium carbonate, 0.5 parts zinc lactate, and 120 parts cereals.

[0009] Furthermore, the weight ratio of quercetin to malic acid is 9:8 to 9:5.

[0010] Furthermore, the weight ratio of the proanthocyanidins to the malic acid is 23:20 to 31:24.

[0011] In a second aspect, the present invention provides a method for preparing a composition having an insulin resistance reversal component, comprising:

[0012] Step S1: Extract the quercetin, proanthocyanidins and malic acid from the berries;

[0013] Step S2: Grind the grains in an ultra-fine grinder, and then sieve them to obtain grain powder;

[0014] Step S3: Add 27-36 parts of quercetin, 23-31 parts of proanthocyanidins, 20-24 parts of malic acid, 1.5-2 parts of magnesium carbonate, 0.2-0.6 parts of zinc lactate and 100-150 parts of grains to a mixing device, and stir and mix the substances evenly to obtain the composition containing the insulin resistance reversing component;

[0015] Step S4: Dispense the composition.

[0016] Further, in step S1, the extraction of quercetin, proanthocyanidins, and malic acid from the berries specifically includes:

[0017] Step S11: Press the berries into juice, add ethanol to obtain an extract;

[0018] Step S12: Filter the extract, evaporate the extract to obtain a concentrated solution;

[0019] Step S13: Separate and purify quercetin, proanthocyanidins and malic acid in the concentrate by column chromatography;

[0020] Step S14: Crystallize the purified quercetin solution, proanthocyanidin solution, and malic acid solution.

[0021] Further, in step S11, the concentration of ethanol is 50% to 60%, the volume ratio of the fruit juice to ethanol is 1:1 to 1:3, and the extraction temperature is 30 to 45°C.

[0022] Further, in step S13, the eluent for the column chromatography is an ethyl acetate solution and a formic acid solution.

[0023] Furthermore, in step S13, the purity of the collected separated fractions is detected at preset time intervals, and the preset time intervals are adjusted according to the purity.

[0024] Compared with the prior art, the beneficial effects of the present invention are that the composition of the present invention, through the synergistic effect of quercetin, proanthocyanidins and malic acid, can increase the sensitivity of cells to fructose, stimulate insulin secretion and improve fructose metabolism, thereby reversing insulin resistance.

[0025] Furthermore, by combining magnesium carbonate and zinc lactate, the secretion rate of insulin and the absorption rate of fructose by cells can be increased, thereby enhancing the efficacy of the composition.

[0026] Furthermore, by precisely controlling the dosage of each effective ingredient, the therapeutic effect of this composition can be accurately predicted. Compared with existing formulations, it has a better effect and can effectively treat insulin resistance and regulate metabolic disorders in the body.

[0027] Furthermore, by extracting components that reverse insulin resistance from natural plants, adverse reactions can be avoided. This method is suitable for a wide range of people, is both medicinal and edible, and has high patient acceptance. Attached Figure Description

[0028] Figure 1 This is a flowchart illustrating a method for preparing a composition containing an insulin resistance reversal component according to an embodiment of the present invention. Detailed Implementation

[0029] The following specific examples illustrate the implementation of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and various details in this specification can also be modified or changed based on different viewpoints and applications without departing from the spirit of the present invention.

[0030] Before further describing specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terminology used in the embodiments of the present invention is for describing specific embodiments and not for limiting the scope of protection of the present invention.

[0031] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in the invention, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0032] It is worth noting that the raw materials used in this invention are all commercially available products, and therefore their sources are not specifically limited.

[0033] In this embodiment of the invention, a composition having an insulin resistance reversal component is provided, the composition comprising quercetin, proanthocyanidins, malic acid, magnesium carbonate, zinc lactate, and cereals.

[0034] Specifically, quercetin can stimulate pancreatic β cells to secrete insulin, inhibit glycogen synthesis, and reduce the amount of fructose released into the bloodstream, thereby controlling blood sugar levels.

[0035] Specifically, the proanthocyanidins have anti-inflammatory and antioxidant effects, can enhance cell sensitivity to insulin, regulate the insulin signaling pathway, and thus enhance cell sensitivity to insulin.

[0036] Specifically, the malic acid has a hypoglycemic effect, can promote the metabolism of fructose, reduce the concentration of fructose in the blood, and improve the body's metabolic level.

[0037] In this embodiment of the invention, quercetin, proanthocyanidins and malic acid work synergistically to increase the sensitivity of cells to fructose, stimulate insulin secretion and improve fructose metabolism, thereby reversing insulin resistance.

[0038] Specifically, the magnesium in the magnesium carbonate can promote the absorption of fructose by cells and work synergistically with the proanthocyanidins to increase the absorption rate of fructose by cells and further reduce the concentration of fructose in the blood.

[0039] Specifically, the zinc element in the zinc lactate participates in stimulating pancreatic β-cells to synthesize and secrete insulin, and works synergistically with the quercetin to further maintain stable insulin levels.

[0040] In this embodiment of the invention, the combination of magnesium carbonate and zinc lactate can enhance the secretion rate of insulin and the absorption rate of fructose by cells, thereby enhancing the efficacy of the composition and further reversing insulin resistance.

[0041] Specifically, the dietary fiber in the grains can slow down the digestion and absorption of carbohydrates. The high-quality carbohydrates in the grains provide the body with sustained energy, help control blood sugar, reduce blood sugar fluctuations, and avoid metabolic disorders.

[0042] In this embodiment of the invention, the composition comprises, by weight, 27-36 parts quercetin, 23-31 parts proanthocyanidins, 20-24 parts malic acid, 1.5-2 parts magnesium carbonate, 0.2-0.6 parts zinc lactate, and 100-150 parts cereals.

[0043] In this embodiment of the invention, the preferred composition by weight is: 34 parts quercetin, 25 parts proanthocyanidins, 21.5 parts malic acid, 1.7 parts magnesium carbonate, 0.5 parts zinc lactate, and 120 parts cereals.

[0044] According to claim 2, the composition having an insulin resistance reversal component, wherein the weight ratio of quercetin to malic acid is 9:8 to 9:5.

[0045] Specifically, the weight ratio of quercetin to malic acid is preferably 34:21.5.

[0046] In this embodiment of the invention, the weight ratio of proanthocyanidins to malic acid is 23:20 to 31:24.

[0047] Specifically, the weight ratio of the proanthocyanidins to the malic acid is preferably 25:21.5.

[0048] Specifically, by precisely controlling the dosage of each effective ingredient, the therapeutic effect of the composition can be accurately predicted. Compared with existing drug-food formulations, it has a better effect and can effectively treat insulin resistance and regulate diabetic metabolic disorders.

[0049] Please see Figure 1 This is a flowchart of a method for preparing a composition containing an insulin resistance reversal component according to an embodiment of the present invention.

[0050] In this embodiment of the invention, a method for preparing a composition having an insulin resistance reversal component includes:

[0051] Step S1: Extract the quercetin, proanthocyanidins and malic acid from the berries;

[0052] Step S2: Grind the grains in an ultra-fine grinder, and then sieve them to obtain grain powder;

[0053] Step S3: Add 27-36 parts of quercetin, 23-31 parts of proanthocyanidins, 20-24 parts of malic acid, 1.5-2 parts of magnesium carbonate, 0.2-0.6 parts of zinc lactate and 100-150 parts of grains to a mixing device, and stir and mix the substances evenly to obtain the composition containing the insulin resistance reversing component;

[0054] Step S4: Dispense the composition.

[0055] Specifically, the berries include any one of strawberries, blueberries, grapes, and mulberries.

[0056] Specifically, the grains include any one of oats, buckwheat, black rice, and quinoa.

[0057] Specifically, the crushed grains are passed through a 300-mesh sieve.

[0058] In this embodiment of the invention, step S1, extracting the quercetin, proanthocyanidins, and malic acid from the berries specifically includes:

[0059] Step S11: Press the berries into juice, add ethanol to obtain an extract;

[0060] Step S12: Filter the extract, evaporate the extract to obtain a concentrated solution;

[0061] Step S13: Separate and purify quercetin, proanthocyanidins and malic acid in the concentrate by column chromatography;

[0062] Step S14: Crystallize the purified quercetin solution, proanthocyanidin solution, and malic acid solution.

[0063] Specifically, the crystallized quercetin crystals, proanthocyanidin crystals, and malic acid crystals are ground into powder and passed through a 300-mesh sieve.

[0064] Specifically, by extracting components that reverse insulin resistance from natural plants, adverse reactions can be avoided. It is suitable for a wide range of people, is both a food and a medicine, and is highly accepted by patients.

[0065] In this embodiment of the invention, in step S11, the concentration of ethanol is 50% to 60%, the volume ratio of the fruit juice to the ethanol is 1:1 to 1:3, and the extraction temperature is 30 to 45°C.

[0066] Specifically, the concentration of the ethanol is preferably 55%.

[0067] Specifically, the volume ratio of the fruit juice to the ethanol is preferably 1:2.

[0068] Specifically, the extraction temperature is preferably 35°C.

[0069] In this embodiment of the invention, in step S13, the eluent for column chromatography is an ethyl acetate solution and a formic acid solution.

[0070] Specifically, the packing material inside the chromatography column in the column chromatography is a gel.

[0071] Specifically, the volume ratio of the ethyl acetate solution to the formic acid solution is preferably 1:15.

[0072] In this embodiment of the invention, in step S13, the purity of the collected separated fractions is detected at preset time intervals, and the preset time intervals are adjusted according to the purity.

[0073] Specifically, the purity of the separated fractions collected within the preset time period is detected by liquid chromatography.

[0074] Specifically, the preset time period is denoted as T0, and T0 = 20 min is set.

[0075] Specifically, the preset time period is adjusted based on the comparison result between the purity and the preset purity.

[0076] If the purity is greater than or equal to the preset purity, it means that the purity meets the standard and there is no need to adjust the preset time period.

[0077] When the purity is less than the preset purity, an adjustment coefficient is determined based on the difference between the purity and the preset purity to adjust the preset time period.

[0078] Specifically, the purity is denoted as P, the preset purity is denoted as P0, P0 = 95%, the difference between the purity and the preset purity is denoted as ΔH, and ΔH = P0 - P.

[0079] Specifically, the adjustment coefficient is determined based on the comparison result between the difference and the preset difference.

[0080] If the difference is less than a first preset difference, the preset time period is adjusted by a first adjustment coefficient.

[0081] Under the condition that the difference is greater than or equal to the first preset difference and less than the second preset difference, it is determined that the preset time period is adjusted by the second adjustment coefficient;

[0082] Under the condition that the difference is greater than or equal to the second preset difference, it is determined that the preset time period is adjusted by a third adjustment coefficient;

[0083] Specifically, the first preset difference is denoted as ΔH1, and ΔH1 = 20% is set; the second preset difference is denoted as ΔH2, and ΔH2 = 40% is set; the first adjustment coefficient is denoted as X1, and X1 = 0.75 is set; the second adjustment coefficient is denoted as X2, and X2 = 0.5 is set; the third adjustment coefficient is denoted as X3, and X3 = 0.2 is set; the adjusted preset time period is denoted as T0', T0' = XiT0, and i = 1, 2, 3.

[0084] The present invention will be illustrated and explained below through specific embodiments.

[0085] Example 1:

[0086] Raw material composition (parts by weight): 34 parts quercetin powder, 25 parts proanthocyanidin powder, 21.5 parts malic acid powder, 1.7 parts magnesium carbonate powder, 0.5 parts zinc lactate powder and 120 parts quinoa powder.

[0087] Preparation method: 34 parts of quercetin powder, 25 parts of proanthocyanidin powder, 21.5 parts of malic acid powder, 1.7 parts of magnesium carbonate powder, 0.5 parts of zinc lactate powder and 120 parts of quinoa powder are added to a mixing device, and the mixing device stirs and mixes the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0088] Example 2:

[0089] Raw material composition (parts by weight): 27 parts quercetin powder, 31 parts proanthocyanidin powder, 24 parts malic acid powder, 1.5 parts magnesium carbonate powder, 0.2 parts zinc lactate powder and 110 parts oat flour.

[0090] Preparation method: 27 parts quercetin powder, 31 parts proanthocyanidin powder, 24 parts malic acid powder, 1.5 parts magnesium carbonate powder, 0.2 parts zinc lactate powder and 110 parts oat flour are added to a mixing device and the mixing device is used to stir and mix the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0091] Example 3:

[0092] Raw material composition (parts by weight): 36 parts quercetin powder, 23 parts proanthocyanidin powder, 20 parts malic acid powder, 1.6 parts magnesium carbonate powder, 0.3 parts zinc lactate powder and 120 parts buckwheat flour.

[0093] Preparation method: 36 parts of quercetin powder, 23 parts of proanthocyanidin powder, 20 parts of malic acid powder, 1.6 parts of magnesium carbonate powder, 0.3 parts of zinc lactate powder and 120 parts of buckwheat flour are added to a mixing device, and the mixing device stirs and mixes the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0094] Example 4:

[0095] Raw material composition (parts by weight): 31 parts quercetin powder, 27 parts proanthocyanidin powder, 22 parts malic acid powder, 1.8 parts magnesium carbonate powder, 0.4 parts zinc lactate powder and 130 parts oat flour.

[0096] Preparation method: 31 parts of quercetin powder, 27 parts of proanthocyanidin powder, 22 parts of malic acid powder, 1.8 parts of magnesium carbonate powder, 0.4 parts of zinc lactate powder and 130 parts of oat flour are added to a mixing device, and the mixing device stirs and mixes the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0097] Example 5:

[0098] Raw material composition (parts by weight): 29 parts quercetin powder, 25 parts proanthocyanidin powder, 22.5 parts malic acid powder, 1.9 parts magnesium carbonate powder, 0.25 parts zinc lactate powder and 135 parts oat flour.

[0099] Preparation method: 29 parts of quercetin powder, 25 parts of proanthocyanidin powder, 22.5 parts of malic acid powder, 1.9 parts of magnesium carbonate powder, 0.25 parts of zinc lactate powder and 135 parts of oat flour are added to a mixing device, and the mixing device stirs and mixes the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0100] Example 6:

[0101] Raw material composition (parts by weight): 35 parts quercetin powder, 30 parts proanthocyanidin powder, 21 parts malic acid powder, 1.6 parts magnesium carbonate powder, 0.3 parts zinc lactate powder and 135 parts black rice powder.

[0102] Preparation method: 35 parts of quercetin powder, 30 parts of proanthocyanidin powder, 21 parts of malic acid powder, 1.6 parts of magnesium carbonate powder, 0.3 parts of zinc lactate powder and 135 parts of black rice powder are added to a mixing device. The mixing device stirs and mixes the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0103] Example 7:

[0104] Raw material composition (parts by weight): 30 parts quercetin powder, 26 parts proanthocyanidin powder, 23 parts malic acid powder, 1.7 parts magnesium carbonate powder, 0.3 parts zinc lactate powder and 120 parts quinoa powder.

[0105] Preparation method: 30 parts of quercetin powder, 26 parts of proanthocyanidin powder, 23 parts of malic acid powder, 1.7 parts of magnesium carbonate powder, 0.3 parts of zinc lactate powder and 120 parts of quinoa powder are added to a mixing device, and the mixing device stirs and mixes the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0106] Example 8:

[0107] Raw material composition (parts by weight): 33 parts quercetin powder, 26 parts proanthocyanidin powder, 21 parts malic acid powder, 1.8 parts magnesium carbonate powder, 0.35 parts zinc lactate powder and 130 parts oat flour.

[0108] Preparation method: 33 parts of quercetin powder, 26 parts of proanthocyanidin powder, 21 parts of malic acid powder, 1.8 parts of magnesium carbonate powder, 0.35 parts of zinc lactate powder and 130 parts of oat flour are added to a mixing device, and the mixing device stirs and mixes the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0109] Comparative Example 1:

[0110] Raw material composition (parts by weight): 34 parts quercetin powder, 25 parts proanthocyanidin powder, 0 parts malic acid powder, 1.7 parts magnesium carbonate powder, 0.5 parts zinc lactate powder and 120 parts quinoa powder.

[0111] Preparation method: 34 parts of quercetin powder, 25 parts of proanthocyanidin powder, 0 parts of malic acid powder, 1.7 parts of magnesium carbonate powder, 0.5 parts of zinc lactate powder and 120 parts of quinoa powder are added to a mixing device, and the mixing device stirs and mixes the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0112] Comparative Example 2:

[0113] Raw material composition (parts by weight): 0 parts quercetin powder, 25 parts proanthocyanidin powder, 21.5 parts malic acid powder, 1.7 parts magnesium carbonate powder, 0.5 parts zinc lactate powder and 120 parts quinoa powder.

[0114] Preparation method: 0 parts quercetin powder, 25 parts proanthocyanidin powder, 21.5 parts malic acid powder, 1.7 parts magnesium carbonate powder, 0.5 parts zinc lactate powder and 120 parts quinoa powder are added to a mixing device and the mixing device is used to stir and mix the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0115] Comparative Example 3:

[0116] Raw material composition (parts by weight): 34 parts quercetin powder, 0 parts proanthocyanidin powder, 21.5 parts malic acid powder, 1.7 parts magnesium carbonate powder, 0.5 parts zinc lactate powder and 120 parts quinoa powder.

[0117] Preparation method: 34 parts of quercetin powder, 0 parts of proanthocyanidin powder, 21.5 parts of malic acid powder, 1.7 parts of magnesium carbonate powder, 0.5 parts of zinc lactate powder and 120 parts of quinoa powder are added to a mixing device, and the mixing device stirs and mixes the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0118] Comparative Example 4:

[0119] Raw material composition (parts by weight): 34 parts quercetin powder, 25 parts proanthocyanidin powder, 0 parts malic acid powder, 1.7 parts magnesium carbonate powder, 0.5 parts zinc lactate powder and 120 parts quinoa powder.

[0120] Preparation method: 34 parts of quercetin powder, 25 parts of proanthocyanidin powder, 0 parts of malic acid powder, 1.7 parts of magnesium carbonate powder, 0.5 parts of zinc lactate powder and 120 parts of quinoa powder are added to a mixing device, and the mixing device stirs and mixes the substances evenly to obtain the composition containing the insulin resistance reversing component.

[0121] I. Animal Experiments

[0122] Test method:

[0123] Several mice were fed a high-sugar, high-fat diet for 10 weeks. After fasting for 8 hours, fasting blood glucose (FBG) was measured. Mice with FBG ≥ 12 mmol / L were considered to have successfully established the model. 112 mice that successfully established the model were fed for another 4 weeks and then randomly divided into 14 groups of 8 mice each. These groups were set as the model control group, positive control group, groups 1-8 of Examples, and groups 1-4 of Comparative Examples. In addition, 8 normal mice were selected as the blank control group.

[0124] The example groups and comparative groups were administered the above-mentioned corresponding compositions by gavage, the positive control group was administered metformin by gavage, and the model control group and blank control group were administered physiological saline by gavage. The dosage of the composition in each example group and comparative group was 20 g / (kg·d), and the dosage of metformin in the positive control group was 150 mg / (kg·d). The composition and metformin in the example group and comparative group were mixed with water to prepare a suspension before being administered by gavage. The gavage volume was 0.1 mL / 10 g / day, 3 times a day, for 4 consecutive weeks. After 4 weeks of administration, fasting blood glucose (FBG) and fasting insulin (FINS) were measured in mice. The insulin resistance index (HOMA-IR) and insulin sensitivity index (ISI) were calculated. The calculation formulas were: HOMA-IR = FBG × FINS / 22.5 and ISI = ln[1 / (FBG × FINS)]. The animal experiment results are shown in Table 1.

[0125] Table 1: Results of animal experiments

[0126]

[0127]

[0128] According to the statistical results in Table 1, the fasting blood glucose (FBG), fasting insulin (FINS), and insulin resistance index (HOMA-IR) values ​​of mice administered the compositions of Examples 1-8 of this invention by gavage were significantly lower than those of the model control group, while the insulin sensitivity index (ISI) value was significantly higher. The therapeutic effect of reversing insulin resistance was obvious. In particular, the therapeutic effect of the composition in Example 1 was the most obvious and similar to that of metformin in the positive control group. The fasting blood glucose (FBG), fasting insulin (FINS), and insulin resistance index (HOMA-IR) values ​​of mice in Comparative Examples 1-8 were lower than those of the model control group, while the insulin sensitivity index (ISI) value was higher, but the effect was not as good as that of the compositions in Examples 1-8.

[0129] II. Clinical Trials

[0130] The results of animal experiments showed that the composition corresponding to Example 1 was the most effective. Clinical trials were conducted using the composition corresponding to Example 1. This trial included 120 patients aged 20 to 60 years with insulin resistance symptoms. The patients took the composition for 10 weeks. Fasting blood glucose (FBG) and fasting insulin (FINS) were measured before and after treatment. The insulin resistance index (HOMA-IR) and insulin sensitivity index (ISI) were calculated before and after treatment. The clinical treatment effect is shown in Table 2.

[0131] Table 2: Clinical Treatment Efficacy

[0132] FBG (mmol / L) FINS (mIU / L) ISI HOMA-IR Before treatment 12.06±2.91 15.28±1.26 -5.21±-0.43 8.19±2.41 After treatment 6.51±1.67 7.23±0.96 -3.85±-0.31 2.09±0.88

[0133] As shown in Tables 1 and 2, the composition of the present invention can reduce fasting blood glucose (FBG), fasting insulin (FINS) and insulin resistance index (HOMA-IR), and improve insulin sensitivity index (ISI). The active ingredients are clearly identified, and the components work synergistically to achieve significant therapeutic effects.

[0134] The technical solution of the present invention has been described above with reference to the preferred embodiments shown in the accompanying drawings. However, it will be readily understood by those skilled in the art that the scope of protection of the present invention is obviously not limited to these specific embodiments. Without departing from the principles of the present invention, those skilled in the art can make equivalent changes or substitutions to the relevant technical features, and the technical solutions after these changes or substitutions will all fall within the scope of protection of the present invention.

Claims

1. A composition having an insulin resistance reversal component, characterized in that, The composition comprises, by weight, 27-36 parts quercetin, 23-31 parts proanthocyanidins, 20-24 parts malic acid, 1.5-2 parts magnesium carbonate, 0.2-0.6 parts zinc lactate, and 100-150 parts cereals.

2. The composition having an insulin resistance reversal component according to claim 1, characterized in that, The composition comprises, by weight, 34 parts quercetin, 25 parts proanthocyanidins, 21.5 parts malic acid, 1.7 parts magnesium carbonate, 0.5 parts zinc lactate, and 120 parts cereals.

3. The composition having an insulin resistance reversal component according to claim 1, characterized in that, The weight ratio of quercetin to malic acid is 9:8 to 9:

5.

4. The composition having an insulin resistance reversal component according to claim 1, characterized in that, The weight ratio of the proanthocyanidins to the malic acid is 23:20 to 31:

24.

5. A method for preparing a composition having an insulin resistance reversal component as described in any one of claims 1 to 4, characterized in that, include: Step S1: Extract the quercetin, proanthocyanidins and malic acid from the berries; Step S2: Grind the grains in an ultra-fine grinder, and then sieve them to obtain grain powder; Step S3: Add 27-36 parts of quercetin, 23-31 parts of proanthocyanidins, 20-24 parts of malic acid, 1.5-2 parts of magnesium carbonate, 0.2-0.6 parts of zinc lactate and 100-150 parts of grains to a mixing device, and stir and mix the substances evenly to obtain the composition containing the insulin resistance reversing component; Step S4: Dispense the composition.

6. The method for preparing the composition having an insulin resistance reversal component according to claim 5, characterized in that, In step S1, the extraction of quercetin, proanthocyanidins, and malic acid from the berries specifically includes: Step S11: Press the berries into juice, add ethanol to obtain an extract; Step S12: Filter the extract, evaporate the extract to obtain a concentrated solution; Step S13: Separate and purify quercetin, proanthocyanidins and malic acid in the concentrate by column chromatography; Step S14: Crystallize the purified quercetin solution, proanthocyanidin solution, and malic acid solution.

7. The method for preparing the composition having an insulin resistance reversal component according to claim 6, characterized in that, In step S11, the concentration of ethanol is 50%~60%, the volume ratio of fruit juice to ethanol is 1:1~1:3, and the extraction temperature is 30~45℃.

8. The method for preparing the composition having an insulin resistance reversal component according to claim 7, characterized in that, In step S13, the eluent for column chromatography is an ethyl acetate solution and a formic acid solution.

9. The method for preparing the composition having an insulin resistance reversal component according to claim 6, characterized in that, In step S13, the purity of the collected separated fractions is detected at preset time intervals, and the preset time intervals are adjusted according to the purity.

Images